CRNX vs. ERAS

Last updated Aug 1, 2026

CRNX (Crinetics Pharmaceuticals, Inc.) and ERAS (Erasca, Inc.) are both stocks. Both operate in the Biotechnology industry within the Healthcare sector. Over the past 5 years, CRNX returned 35.96%/yr vs -2.87%/yr for ERAS. Their 0.36 correlation means their historical movements had little consistent relationship.

Performance

CRNX vs. ERAS - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Crinetics Pharmaceuticals, Inc. (CRNX) and Erasca, Inc. (ERAS). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, CRNX achieves a 79.42% return, which is significantly lower than ERAS's 387.90% return.

CRNX

• 1D: -0.13%
• 1M: 97.77%
• 6M: 67.24%
• YTD: 79.42%
• 1Y: 200.00%
• 3Y*: 62.54%
• 5Y*: 35.96%
• 10Y*: —
• ALL TIME*: 20.04%

ERAS

• 1D: -2.84%
• 1M: -1.73%
• 6M: 72.69%
• YTD: 387.90%
• 1Y: 1,205.76%
• 3Y*: 89.91%
• 5Y*: -2.87%
• 10Y*: —
• ALL TIME*: 2.66%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Liquidity Comparison

Position	Avg. Volume Value (2W)	Avg. Volume Value (1M)	Avg. Volume Value (3M)
CRNX Crinetics Pharmaceuticals, Inc.	$259.03M	$689.74M	$264.69M
ERAS Erasca, Inc.	$64.00M	$90.42M	$77.82M

CRNX vs. ERAS - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021
CRNX Crinetics Pharmaceuticals, Inc.	79.42%	-8.96%	43.70%	94.43%	-35.59%	44.14%
ERAS Erasca, Inc.	387.90%	48.21%	17.84%	-50.58%	-72.34%	-2.01%

Correlation

The correlation between CRNX and ERAS is 0.20, which is low. Their historical price movements had little consistent relationship.

	Correlation
Correlation (1Y) Focuses on recent behavior, but can change the most.	0.20
Correlation (3Y) Balances recent behavior with more history.	0.33
Correlation (5Y) Shows whether the relationship held over a longer period.	0.37
Correlation (All Time) Calculated using the full available price history since Jul 16, 2021	0.36

The correlation between CRNX and ERAS shifts across timeframes, from 0.20 (1 year) to 0.37 (5 years), reflecting how their relationship changes across market environments.

Fundamentals

Market Cap CRNX : $8.84B ERAS : $6.30B
EPS CRNX : -$5.09 ERAS : -$0.95
PB Ratio CRNX : 6.79 ERAS : 14.04
Total Revenue (TTM) CRNX : $15.79M ERAS : $0.00
Gross Profit (TTM) CRNX : $16.05M ERAS : -$743.00K
EBITDA (TTM) CRNX : -$531.75M ERAS : -$279.47M

Return for Risk

CRNX vs. ERAS — Risk / Return Rank

Compare historical risk-adjusted metric ranks over the past 12 months.

CRNX

CRNX Risk / Return Rank: 93
CRNX Sharpe Ratio Rank: 88
CRNX Sortino Ratio Rank: 98
CRNX Omega Ratio Rank: 97
CRNX Calmar Ratio Rank: 94
CRNX Martin Ratio Rank: 89

ERAS

ERAS Risk / Return Rank: 99
ERAS Sharpe Ratio Rank: 100
ERAS Sortino Ratio Rank: 99
ERAS Omega Ratio Rank: 99
ERAS Calmar Ratio Rank: 100
ERAS Martin Ratio Rank: 100

The rank (0–100) uses a weighted average of the Sharpe, Sortino, Omega, Calmar, and Martin percentile ranks for the trailing 12 months. Higher means stronger historical risk-adjusted performance within the peer group.

CRNX vs. ERAS - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Crinetics Pharmaceuticals, Inc. (CRNX) and Erasca, Inc. (ERAS). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.

	CRNX	ERAS	Difference
Sharpe ratio: Return per unit of total volatility	1.71	11.46	-9.75
Sortino ratio: Return per unit of downside risk	4.65	5.02	-0.37
Omega ratio: Gain probability vs. loss probability	1.58	1.82	-0.24
Calmar ratio: Return relative to maximum drawdown	4.58	20.11	-15.53
Martin ratio: Return relative to average drawdown	9.07	59.39	-50.31

CRNX vs. ERAS - Sharpe Ratio Comparison

The current CRNX Sharpe Ratio is 1.71, which is lower than the ERAS Sharpe Ratio of 11.46. The chart below compares the historical Sharpe Ratios of CRNX and ERAS, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Drawdowns

CRNX vs. ERAS - Drawdown Comparison

The maximum CRNX drawdown since its inception was -68.70%, smaller than the maximum ERAS drawdown of -95.65%. Use the drawdown chart below to compare losses from any high point for CRNX and ERAS.

Drawdown Indicators

	CRNX	ERAS	Difference
Max Drawdown Largest peak-to-trough decline	-68.70%	-95.65%	+26.95%
Max Drawdown (1Y) Largest decline over 1 year	-42.21%	-59.46%	+17.25%
Max Drawdown (3Y) Largest decline over 3 years	-57.88%	-67.68%	+9.80%
Max Drawdown (5Y) Largest decline over 5 years	-57.88%	-95.65%	+37.77%
Current Drawdown Current decline from peak	-0.46%	-25.43%	+24.97%
Average Drawdown Average peak-to-trough decline	-36.98%	-73.43%	+36.45%
Ulcer Index Depth and duration of drawdowns from previous peaks	21.27%	20.10%	+1.17%

Volatility

CRNX vs. ERAS - Volatility Comparison

Crinetics Pharmaceuticals, Inc. (CRNX) has a higher volatility of 68.84% compared to Erasca, Inc. (ERAS) at 20.49%. This indicates that CRNX's price experiences larger fluctuations and is considered to be riskier than ERAS based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	CRNX	ERAS	Difference
Volatility (1M) Calculated over the trailing 1-month period	68.84%	20.49%	+48.35%
Volatility (6M) Calculated over the trailing 6-month period	76.63%	86.24%	-9.61%
Volatility (1Y) Calculated over the trailing 1-year period	113.40%	104.83%	+8.57%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	77.55%	83.41%	-5.86%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	74.07%	83.32%	-9.25%

Dividends

CRNX vs. ERAS - Dividend Comparison

Neither CRNX nor ERAS has paid dividends to shareholders.

Tickers have no history of dividend payments

Financials

Frequently Asked Questions

Can I hold both CRNX and ERAS in my portfolio?

CRNX and ERAS have a correlation of 0.20, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, CRNX or ERAS?

CRNX has higher volatility (68.84%) compared to ERAS (20.49%). In terms of maximum drawdown, CRNX dropped -68.70% vs ERAS's -95.65%.

Which has better risk-adjusted returns?

ERAS currently has the higher Sharpe Ratio (11.46 vs 1.71), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.